NCT06047379 2026-03-02
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Recruiting
Neonc Technologies, Inc.
Gruppo Oncologico Italiano di Ricerca Clinica
Institut Bergonié
Memorial Sloan Kettering Cancer Center
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)